Siremadlin (HDM201) is well tolerated and demonstrates clinical activity in patients with acute myeloid leukemia who have relapsed after allogeneic stem cell transplantation: A subset analysis of safety and preliminary efficacy Meeting Abstract
| Authors: | Stein, E. M.; Chromik, J.; Carpio, C.; Mous, R.; Kiladjian, J. J.; Alatrash, G.; Curti, A.; Craddock, C.; Schmid, C.; Zeiser, R.; Edldjerou, L. K.; Weber, H. J. J.; Fabre, C.; Scott, J.; De Angelo, D. J. |
| Abstract Title: | Siremadlin (HDM201) is well tolerated and demonstrates clinical activity in patients with acute myeloid leukemia who have relapsed after allogeneic stem cell transplantation: A subset analysis of safety and preliminary efficacy |
| Meeting Title: | 63rd Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 138 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2021 Dec 11-14 |
| Meeting Location: | Atlanta, GA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2021-11-23 |
| Language: | English |
| ACCESSION: | WOS:000736413905234 |
| DOI: | 10.1182/blood-2021-149751 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 3417 -- Hybrid meeting, also took place online -- Source: Wos |
